The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer Axillary dissection is the standard management of the axilla in invasive ...

Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...

Response-guided axillary treatment using an approach known as the MARI protocol can safely spare many women with node-positive breast cancer from axillary lymph node dissection (ALND) after ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

SAN ANTONIO -- Neoadjuvant chemotherapy that downstaged positive lymph nodes to negative led to a low rate of invasive breast cancer recurrence with either targeted axillary dissection (TAD) or ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...